PetMed Express, Inc. (PETS)
| Market Cap | 26.10M -49.7% |
| Revenue (ttm) | 168.86M -20.3% |
| Net Income | -29.28M |
| EPS | -1.38 |
| Shares Out | 21.05M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 46,811 |
| Open | 1.220 |
| Previous Close | 1.240 |
| Day's Range | 1.202 - 1.250 |
| 52-Week Range | 1.150 - 4.100 |
| Beta | 0.84 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 10, 2026 |
About PETS
PetMed Express, Inc., together with its subsidiaries, operates as a pet pharmacy in the United States. The company markets prescription and non-prescription pet medications, health products, and other supplies for dogs, cats, and horses. It offers non-prescription medications and supplies, such as flea and tick control products, bone and joint care products, vitamins, treats, nutritional supplements, hygiene products, and household pet supplies; and prescription medications, including heartworm preventatives, flea and tick preventatives, arthri... [Read more]
Financial Performance
In fiscal year 2026, PetMed Express's revenue was $179.02 million, a decrease of -21.13% compared to the previous year's $226.97 million. Losses were -$57.29 million, 813.5% more than in 2025.
Financial StatementsNews
PetMed Express, Inc. to Report Second Quarter Fiscal Year 2027 Financial Results on Tuesday, November 10, 2026
DELRAY BEACH, Fla., Oct. 27, 2026 (GLOBE NEWSWIRE) -- PetMed Express, Inc., dba PetMeds and parent company of PetCareRx, (Nasdaq: PETS) today announced it will report financial results for the second ...
PetMeds Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
DELRAY BEACH, Fla., Oct. 02, 2026 (GLOBE NEWSWIRE) -- PetMed Express, Inc., dba PetMeds and parent company of PetCareRx (Nasdaq: PETS), today announced that PetMeds recently granted equity awards prev...
PetMed Express price target lowered to $1.40 from $2.15 at Morgan Stanley
Morgan Stanley analyst Erin Wright lowered the firm’s price target on PetMed Express (PETS) to $1.40 from $2.15 and keeps an Underweight rating on the shares.
PetMed Express appoints Elkeles as new independent director
PetMed Express (PETS), parent company of PetCareRx, announced the appointment of Tamar Elkeles, PhD as a new independent director and Chair of the Compensation and Human Capital Committee, effective S...
PetMeds Enhances Board of Directors with Appointment of Tamar Elkeles as New Independent Director
Dr. Elkeles Brings Deep Experience and Proven Track Record in Shaping Human Capital Strategy to Support Strategic Growth and Operational Execution Dr. Elkeles Brings Deep Experience and Proven Track R...
PetMed Express appoints Jeff Willard as CEO
PetMed Express (PETS) announced the appointment of Jeff Willard, as CEO and president, as well as a member of the board of directors, effective September 28, 2026. Willard succeeds Leslie…
PetMeds Appoints Jeff Willard as CEO & President and Announces Board Leadership Transition
Justin Mennen to Succeed Leslie C.G. Campbell as Chair of the Board Following Her Retirement Justin Mennen to Succeed Leslie C.G. Campbell as Chair of the Board Following Her Retirement
PetMed Express appoints Andrew Parry as CTO
PetMed Express (PETS) announced the appointment of Andrew Parry as CTO, effective immediately. Parry will lead the company’s technology strategy, platform architecture and engineering execution across...
PetMeds Appoints Andrew Parry as Chief Technology Officer
DELRAY BEACH, Fla., Sept. 14, 2026 (GLOBE NEWSWIRE) -- PetMed Express, Inc., dba PetMeds and parent company of PetCareRx (Nasdaq: PETS), today announced the appointment of Andrew Parry as Chief Techno...
PetMed Express Earnings Call Transcript: Q1 2027
Q1 net sales declined 19.9% year-over-year to $41 million, but losses narrowed significantly due to cost controls and the absence of impairment charges. Strategic initiatives, including technology upgrades and a new B2B partnership, are improving efficiency and customer acquisition.
PetMed Express Earnings release: Q1 2027
PetMed Express released its Q1 2027 earnings on August 13, 2026, summarizing the period's financial results.
PetMed Express Quarterly report: Q1 2027
PetMed Express has published its Q1 2027 quarterly earnings report on August 13, 2026.
PetMeds® Announces First Quarter Financial Results
DELRAY BEACH, Fla., Aug. 13, 2026 (GLOBE NEWSWIRE) -- PetMed Express, Inc. dba PetMeds and parent company of PetCareRx (NASDAQ: PETS) today announced its financial results for its first quarter ended ...
PetMed Express, Inc. to Report First Quarter Fiscal Year 2027 Financial Results on Thursday, August 13, 2026
DELRAY BEACH, Fla., July 30, 2026 (GLOBE NEWSWIRE) -- PetMed Express, Inc., dba PetMeds and parent company of PetCareRx, (Nasdaq: PETS) today announced it will report financial results for the first q...
PetMed Express enters $37M sale-leaseback transaction for headquarters
PetMed Express (PETS) announced that it has entered into a definitive agreement for a sale-leaseback transaction with an institutional real estate investor involving the company’s headquarters and dis...
PetMeds Announces Proposed Sale-Leaseback of Headquarters and Distribution Center Buildings for $37 Million
DELRAY BEACH, Fla., July 23, 2026 (GLOBE NEWSWIRE) -- PetMed Express, Inc., dba PetMeds and parent company of PetCareRx (Nasdaq: PETS), today announced that it has entered into a definitive agreement ...
PetMeds and Rural King Expand Access to Pet Healthcare Through New Online Pharmacy Platform
DELRAY BEACH, Fla., July 14, 2026 (GLOBE NEWSWIRE) -- PetMed Express, Inc., doing business as PetMeds and parent company of PetCareRx (Nasdaq: PETS), today announced that its new online pet pharmacy o...
PetMed Express confirms $3.00 per share acquisition proposal from SilverCape
PetMed Express (PETS) confirmed that its board of directors has received an unsolicited, non-binding, and conditional proposal from SilverCape Investments to acquire all outstanding shares of the comp...
PetMed Express, Inc. Confirms Receipt of Unsolicited, Non-Binding, and Conditional Acquisition Proposal from SilverCape Investments Limited
DELRAY BEACH, Fla., June 30, 2026 (GLOBE NEWSWIRE) -- PetMed Express, Inc. (“PetMeds” or the “Company”) (Nasdaq: PETS) today confirmed that its Board of Directors (the “Board”) has received an unsolic...
SilverCape revises proposal to acquire PetMed Express for $3.00 per share
SilverCape Investments released an open letter to the board of directors of PetMed Express (PETS) calling on the board to engage with SilverCape on a revised proposal to acquire all…
SilverCape Releases Revised Proposal to Acquire PetMed Express for $3.00 per Share in Cash
Unaccountable Board Led by Chair & Interim CEO Leslie C.G. Campbell Continues to Preside Over Stunning Destruction of Stockholder Value
PetMed Express Proxy statement: Proxy filing
PetMed Express filed a proxy statement on June 25, 2026, providing details for shareholder voting and corporate governance matters.
PetMed Express Proxy statement: Proxy filing
PetMed Express filed a proxy statement on June 25, 2026, providing details for shareholder voting and corporate governance matters.
PetMed Express to continue as public company after receipt of buyout offers
The company stated in its Q4 earnings announcement: “In December 2025, the Company received two unsolicited, non-binding preliminary proposals from two separate third parties to acquire all of the out...
PetMed Express reports Q4 EPS (19c) vs. (56c) last year
Reports Q4 revenue $42.82M vs. $50.76M last year. “We are pleased to report a modest sequential quarterly increase in fourth quarter net sales, demonstrating positive momentum as we close out…